RMD: ResMed — Growth, Pullback, and Near-Term Catalyst

Executive Summary

Company Overview

ResMed Inc develops, manufactures and distributes equipment and digital health solutions for the diagnosis and treatment of sleep-disordered breathing and other chronic respiratory conditions. The company sells CPAP and ventilatory devices, masks and a growing suite of cloud-connected software services for patients and provider partners.

Key Products & Competitive Position

• Core Business: Sleep-disordered breathing devices and related consumables plus connected digital health services that drive recurring revenue.
• Key Products: CPAP devices and masks, non-invasive ventilators, cloud platforms (AirView/ResMed MyAir), and remote-monitoring solutions for hospitals and clinics.
• Competitive Moat: Large installed base, strong brand recognition among clinicians, recurring consumables revenue, and integration of hardware with software and services that increase switching costs.

Recent Developments

ResMed announced its intention to report Q3 fiscal 2026 results on April 30, 2026. The stock has pulled back from its 52-week high and underperformed the market recently, prompting renewed discussion about valuation and growth durability. Analysts continue to update models with several maintaining Buy ratings and raising price targets earlier in the year.

Financial Snapshot

Revenue & Earnings Trends

ResMed has delivered mid-single-digit to low-double-digit revenue growth in recent fiscal years, driven by device sales and recurring revenue from masks and software services. Recent quarters showed healthy operating margins and steady EPS, with TTM EPS at $10.12 which supports the current P/E near 22. Wall Street expects continued EPS growth, and recent commentary suggests analysts anticipate double-digit EPS growth in the coming quarters, though the company’s growth rate has moderated from the peak pandemic-era gains.

Balance Sheet Highlights

The balance sheet is solid, with a current ratio of 3.06 indicating strong short-term liquidity. Debt levels are manageable relative to market cap and cash flow, and free cash generation has been consistent enough to support dividends (yield 1.09%) and share repurchases. The company’s capital allocation focuses on share repurchases and targeted M&A to build software capabilities.

Valuation Analysis

Historical Comparison

ResMed’s current trailing P/E near 22 is below the stock’s recent cyclical peaks but still elevated relative to broader medical device peers. The five-year average P/E has hovered in the low-to-mid 20s, so the current multiple sits around that historical midpoint after the recent pullback.

Fair Value Estimate

Combining a multiples approach and a conservative discounted cash flow view, a fair value range centers in the low-to-mid $270s to high $280s per share, with a blended mid-point near $279. That aligns with several published intrinsic estimates which see roughly 20-35% upside from the current price, depending on growth assumptions.

Competitive Landscape

Key Competitors

Competitive Advantages

• Moat 1: Large installed base creates recurring consumables revenue and high switching costs.
• Moat 2: Integrated hardware-software platform that supports remote monitoring and improves outcomes for care providers.
• Moat 3: Global distribution and strong clinician relationships that make new product adoption efficient.

Earnings Track Record

Recent Earnings History

Guidance Trend

Management has generally provided conservative guidance and emphasized recurring revenue growth from software and consumables. Analysts note guidance revisions have been moderate, and the upcoming Q3 fiscal 2026 report will be closely watched for direction on device demand and subscription uptake.

Analyst Sentiment

Price Targets

• Low: $230
• Mean: $296.87 (+32.2% upside)
• High: $345

Recent Analyst Actions

Citigroup maintained a Buy on RMD on February 2, 2026 and raised its price target to $345 from $330. Several other firms have maintained Buy or Hold with updated models emphasizing software revenue as a multi-year growth driver.

Recent News & Catalysts

Key Developments

• Q3 Earnings Date Announced: ResMed plans to report third quarter fiscal 2026 results on April 30, 2026.
• Share-price Weakness: Recent coverage notes a pullback around 14% over the prior month and questions whether the drop creates opportunity or signals underlying deterioration.
• Analyst Interest: The stock remains featured in GARP screens and some analysts are raising price targets based on recurring revenue growth and margin potential.

Upcoming Catalysts

Technical Outlook

Trend Analysis

The stock pulled back from the 52-week high and has traded lower over the past month. Momentum indicators suggest a cooling phase after a multi-quarter advance. That said, the price remains above the 52-week low and there is evidence of buyer interest around the $200 to $215 zone. Is the recent pullback a durable trend change or a correction that sets up a higher low? That question will likely be settled after the upcoming earnings print.

Key Levels

• Resistance: $250, $280
• Support: $210, $200

Bull vs Bear Case

Risks to Consider

Bottom Line

Action Items for Investors

• Long-term investors: Observe upcoming Q3 results and monitor recurring revenue trajectory before adjusting exposure. Evaluate whether the company’s long-term growth assumptions match your time horizon and risk tolerance.
• Short-term traders: Use the earnings report on April 30, 2026 as a volatility catalyst, and consider discipline around stop levels and position sizing to manage risk.
• Risk management: Track support around $210 and $200. Consider scaling into any position rather than deploying full exposure at a single price given near-term uncertainty.

What to Watch This Week

• Pre-earnings commentary from management and any preannouncements ahead of April 30, 2026.
• Analyst revisions, particularly to EPS and subscription growth forecasts.
• Macro and reimbursement headlines that could influence device ordering or consumables demand.